Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 626

Sort by

Sort Order Select

Journal Articles

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

Kaushik Das, Shiva Keshava, Shabbir A. Ansari, Vijay Kondreddy, Charles T. Esmon, John H. Griffin, Usha R. Pendurthi, L. Vijaya Mohan Rao

Blood (2021) 137 (24): 3428–3442.

https://doi.org/10.1182/blood.2020008417

Published: 2021

Includes: Supplemental data

Journal Articles

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Jhansi Magisetty, Usha R. Pendurthi, Charles T. Esmon, L. Vijaya Mohan Rao

Blood (2020) 135 (25): 2211–2223.

https://doi.org/10.1182/blood.2019003824

Published: 2020

Includes: Supplemental data

Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 2420.

https://doi.org/10.1182/blood-2019-128971

Published: 2019

Journal Articles

Clinical, Laboratory and Molecular Characterization of Factor VII, Factor X and Their Combined Deficiencies in a Tertiary Care Center

Bereczky Zsuzsanna, MD PhD, Speker Marianna, Al-Muhanna Marie, Balogh Gábor, Boda Zoltán, MD PhD DSc, Pfliegler György, MD PhD, Schlammadinger Ágota, MD PhD, Kerényi Adrienn, MD PhD, Csongor Kiss, MD PhD DSc

Blood (2019) 134 (Supplement_1): 2394.

https://doi.org/10.1182/blood-2019-125504

Published: 2019

Journal Articles

Gpibα Engagement Induces Activation of Human Platelet TF and Association with Constitutively Platelet Surface-Bound FVIIa

Olga Panes, Biochemist, M. Francisca Becerra, Biochemist, Roger Valle, Biochemist, Claudia G Sáez, PhD, Patricia Hidalgo, MT, Jaime Pereira, MD, Jennifer Royce, Wolfram Ruf, MD, PhD, Diego Mezzano, MD

Blood (2019) 134 (Supplement_1): 2337.

https://doi.org/10.1182/blood-2019-126359

Published: 2019

Journal Articles

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Blood (2019) 134 (Supplement_1): 2426.

https://doi.org/10.1182/blood-2019-129820

Published: 2019

Journal Articles

Monitoring of Recombinant Activated Coagulation Factor VII (rFVIIa) Therapy in Patients (pts) with Inherited Factor VII (FVII) Deficiency

Gennadii M. Galstian, Olesya A. Polevodova, MD, Elena Yakovleva, MD PhD, Antonina Shchekina, MD, Igor Davydkin, MD PhD, Dmitriy Kudlay, MD PhD

Blood (2019) 134 (Supplement_1): 2412.

https://doi.org/10.1182/blood-2019-124709

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC)

Sara Reda, MD, Franziska Isabelle Winterhagen, Christina Berens, MD, Jens Müller, Johannes Oldenburg, Bernd Pötzsch, MD, Heiko Rühl, MD

Blood (2019) 134 (Supplement_1): 2389.

https://doi.org/10.1182/blood-2019-124731

Published: 2019

Journal Articles

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Xin Ying Lee, Katarina Cepo, Thomas Porstmann

Blood (2019) 134 (Supplement_1): 2419.

https://doi.org/10.1182/blood-2019-122827

Published: 2019

Journal Articles

A Lipid Peroxidation Product, 4-Hydroxy-2-Nonenal, Triggers Intravascular Coagulation and Inflammation through Generation of Tissue Factor-Positive Microvesicles

Shabbir Ansari, PhD, Shiva Keshava Gaddam Bala Krishna, PhD, Usha R. Pendurthi, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 2383.

https://doi.org/10.1182/blood-2019-124498

Published: 2019

Journal Articles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Laurent Burnier, PhD, Mette B Hermit, PhD, Ida Hilden, Mirella Ezban, PhD, Stine L Kjellev, PhDDVM

Blood (2019) 134 (Supplement_1): 2388.

https://doi.org/10.1182/blood-2019-123340

Published: 2019

Journal Articles

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Thomas J. Girard, Nina M. Lasky, Dhanalakshmi S. Anbukumar, George J. Broze, Jr.

Blood (2019) 134 (Supplement_1): 484.

https://doi.org/10.1182/blood-2019-130360

Published: 2019

Journal Articles

Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site

Vijay Kumar Reddy Kondreddy, MSc,PhD, Usha R. Pendurthi, PhD, Xiao Xu, John H. Griffin, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 481.

https://doi.org/10.1182/blood-2019-124976

Published: 2019

Journal Articles

Alterations in Sphingomyelin Metabolism Influences Tissue Factor Procoagulant Activity and the Release of TF-Positive Microvesicles

Jue Wang, PhD, Usha Pendurthi, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 1103.

https://doi.org/10.1182/blood-2019-125933

Published: 2019

Journal Articles

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 1134.

https://doi.org/10.1182/blood-2019-123820

Published: 2019

Journal Articles

Therapeutic Doses of Recombinant FVIIa in Hemophilia Generates Thrombin in Platelet-Dependent and -Independent Manner

Shiva Keshava Gaddam Bala Krishna, PhD, Usha Pendurthi, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 1136.

https://doi.org/10.1182/blood-2019-128474

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Amy Shapiro, Giancarlo Castaman, MD, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, MD, Silva Zupancic-Salek, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1139.

https://doi.org/10.1182/blood-2019-122809

Published: 2019

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Ihosvany Fernandez-Bello, María Teresa Alvarez Román, Mónica Martín, María Isabel Rivas Pollmar, Sara García Barcenilla, Carmen García Martínez, Tamara Cebanu, Paula Acuña, Raul Justo Sanz, Elena Monzón Manzano, Miguel A Canales, MD PhD, Nora Butta, PhD, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1118.

https://doi.org/10.1182/blood-2019-129983

Published: 2019

NARROW

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Clinical, Laboratory and Molecular Characterization of Factor VII, Factor X and Their Combined Deficiencies in a Tertiary Care Center

Gpibα Engagement Induces Activation of Human Platelet TF and Association with Constitutively Platelet Surface-Bound FVIIa

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Monitoring of Recombinant Activated Coagulation Factor VII (rFVIIa) Therapy in Patients (pts) with Inherited Factor VII (FVII) Deficiency

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC)

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

A Lipid Peroxidation Product, 4-Hydroxy-2-Nonenal, Triggers Intravascular Coagulation and Inflammation through Generation of Tissue Factor-Positive Microvesicles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site

Alterations in Sphingomyelin Metabolism Influences Tissue Factor Procoagulant Activity and the Release of TF-Positive Microvesicles

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Therapeutic Doses of Recombinant FVIIa in Hemophilia Generates Thrombin in Platelet-Dependent and -Independent Manner

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only